Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program

Journal of Substance Abuse Treatment

Volumn 43, Issue 4, 2012, Pages 424-432

  Stein, Melissa R ^a   Soloway, Irene J ^a   Jefferson, Karen S ^a   Roose, Robert J ^a   Arnsten, Julia H ^a   Litwin, Alain H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic hepatitis C; Group treatment; HCV; IDU; Methadone maintenance

Indexed keywords

ALPHA2A INTERFERON; BOCEPREVIR; METHADONE; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ADULT; ANAL COMPLAINT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONCURRENT GROUP TREATMENT; DRUG ERUPTION; DYSGEUSIA; FEMALE; GASTROINTESTINAL SYMPTOM; GROUP THERAPY; HEPATITIS C; HUMAN; MALE; MEDITATION; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEROIN DEPENDENCE; HUMANS; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; POLYETHYLENE GLYCOLS; PSYCHOTHERAPY, GROUP; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84868147307     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2012.08.007     Document Type: Article

References (54)

1. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States 1999 through 2002. Annals of Internal Medicine 2006, 138:187-190.
2. Backmund M., Meyer K., Edlin B. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clinical Infectious Diseases 2004, 39(10):1540-1543.
3. Bini E.J., Brau N., Currie S., et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. American Journal of Gastroenterology 2005, 100:1772-1779.
4. Bronson D., Maxwell R. Shared medical appointments: Increasing patient access without increasing physician hours. Cleveland Clinic Journal of Medicine 2008, 71:369-377.
5. Brown L.S., Kritz S.A., Goldsmith R.J., Bini E.J., Rotrosen J., Baker S., et al. Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: The National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2006, 30:315-321.
6. Clanon K., Mueller J., Harank M. Integrating treatment for hepatitis C virus infection into an HIV clinic. Clinical Infectious Diseases 2005, 16:S362-S366.
7. Cullen W., Kelly Y., Stanley J., Langton D., Bury G. Experience of hepatitis C among current or former heroin users attending general practice. Irish Medical Journal 2005, 98:73-74.
8. Davis G.L., Rodriguez J.R. Treatment of chronic hepatitis C in active drug users. The New England Journal of Medicine 2001, 345:215-217.
9. Diaz T., Des Jarlais D.C., Vlahov D., Perlis T.E., Edwards V., Friedman S.R., et al. Factors associated with prevalent hepatitis C: Differences among young adult injection drug users in lower and upper Manhattan, New York City. American Journal of Public Health 2001, 9:23-30.
10. Doab A., Treloar C., Dore G.J. Knowledge and attitudes about treatment for hepatitis C infection and barriers to treatment among current infection drug users in Australia. Clinical Infectious Diseases 2005, 40:2313-2320.
11. EASL Clinical Practice Guidelines Management of hepatitis C virus infection-European Association for the Study of the Liver. Journal of Hepatology 2011, 55(2):245-264.
12. Edlin B., Kresina T., Cargill V., et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clinical Infectious Diseases 2005, 40:S276-S285.
13. Edlin B.R., Seal K.H., Lorvick J., Kral A.H., Ciccarone D.H., Moore L.D., et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users. The New England Journal of Medicine 2001, 345:211-215.
14. Falck-Ytter Y., Kale H., Mullen K., Sarbah S., Sorescu L., McCullough A. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine 2002, 136:288-292.
15. Feuerstadt P., Bunim A.L., Garcia H., Karlitz J.J., Massoumi H., Thosani A.J., et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2010, 51:1137-1143.
16. Fishbein D., Yungtai L., Reinus J.M., Klein R. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. Journal of Acquired Immune Deficiency Syndromes 2004, 37:1367-1375.
17. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1422-1444.
18. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management and treatment of hepatitis C, an update. Hepatology 2009, 49:1335-1374.
19. Gidding H.F., Law M.G., Amin J., et al. Hepatitis C treatment outcomes in Australian clinics. The Medical Journal of Australia 2012, 196(10):633-637.
20. Grebely J., Genoway K., Khara M., et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. The International Journal on Drug Policy 2007, 18:437-443.
21. Grebely J., Knight E., Genoway K.A., et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology & Hepatology 2011, 22(3):270-277.
22. Grebely J., Petoumenos K., Matthews G., et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug and Alcohol Dependence 2010, 107:244-249.
23. Grebely J., Raffa J., Tyndall M., et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. Journal of Viral Hepatitis 2009, 16:352-358.
24. Guadagnino V., Trotta M., Montesano F., et al. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 2007, 102:423-431.
25. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases 2009, 49(4):561-573.
26. Jaber R., Braksmajer A., Trilling J. Group visits: A qualitative review of current research. Journal of the American Board of Family Medicine 2006, 19:276-290.
27. Kanwal F., Hoang T., Spiegel B.M., et al. Predictors of treatment in patients with chronic hepatitis C infection-Role of patient versus nonpatient factors. Hepatology 2007, 46(6):1741-1749.
28. Kramer J.R., Kanwal F., Richardson P., Giordano T.P., Petersen L.A., El-Serag H.B. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: A national study. American Journal of Gastroenterology 2011, 106:483-491.
29. Leshner A.I. Introduction to the special issue: The National Institute on Drug Abuse's (NIDA's) Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors 1997, 11:211-215.
30. Litwin A., Harris K., Nahvi S., et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 2009, 37:32-40.
31. Litwin A., Soloway I., Gourevitch M. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clinical Infectious Diseases 2005, 40:S339-S434.
32. Ly K.N., Xing J., Monina Klevens R., Jiles R.B., Ward J.W., Holmberg S.D. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of Internal Medicine 2012, 156(4):271-278.
33. Meehan K., Hill J., Root L., Kimtis E., Patchett L., Noffsinger E. Group medical appointments: Organization and implementation in the bone marrow transplantation clinic. Supportive Cancer Therapy 2006, 3:84-90.
34. Mehta S., Genberg B., Astemborski J., et al. Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health 2008, 33:126-133.
35. Mehta S.H., Lucas G.M., Mirel L.B., Torbenson M., Higgins Y., Moore R.D., et al. Limited effectivelness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006, 20:2361-2369.
36. Merrill J., Rhodes L., Deyo R., Marlatt G., Bradley K. Mutual mistrust in the medical care of drug users. Journal of General Internal Medicine 2002, 17:327-333.
37. Murrill C., Weeks H., Castrucci B., Weinstock H., Bell B., Spruill C., et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. American Journal of Public Health 2002, 92:385-387.
38. National Institutes of Health National Institutes of Health Consensus Development Conference Statement Management of Hepatitis C: 2002 June 10-12, 2002. HIV Clinical Trials 2003, 4:55.
39. Nelson P.K., Mathers B.M., Cowie B., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011, 378:571-583.
40. Noffsinger E.B. Will drop-in medical appointments (DIGMAs) work in practice?. Permanente Journal 1999, 3:58-67.
41. Norman J., Walsh N.M., Mugavin J., et al. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduction Journal 2008, 5:8.
42. Patrick D.M., Tyndall M.W., Cornelisse P.G., Li K., Sherlock C.H., Rekart M.L., et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Canadian Medical Association Journal 2001, 165:889-895.
43. Schackman B.R., Teixeira P.A., Beeder A.B. Offers of hepatitis C care do not lead to treatment. Journal of Urban Health 2007, 84:455-458.
44. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C infection. The Lancet Infectious Diseases 2005, 5:558-567.
45. Stein M.D., Maksad J., Clarke J. Hepatitis C disease among injection drug users: knowledge, percieved risk and willingness to receive treatment. Drug and Alcohol Dependence 2001, 61:211-215.
46. Stephenson J. Former addicts face barriers to treatment for HCV. Journal of the American Medical Association 2001, 285:1003-1005.
47. Strauss S.M., Astone Twerell J., Munoz-Plaza C.E., Des Jarlais D.C., Gwadz M., Hagan H., et al. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Services Research 2007, 7:39.
48. Substance Abuse and Mental Health Services Administration (SAMSHA) Results from the 2003 National Survey on Drug Use and Health: National Findings 2004, Office of Applied Studies, Rockville, MD.
49. Sylvestre D. Treating hepatitis C virus infection in active substance users. Clinical Infectious Diseases 2005, 40:S321-S324.
50. Sylvestre D., Zweben J. Integrating HCV services for drug users: A model to improve engagement and outcomes. The International Journal on Drug Policy 2007, 18:406-410.
51. Talal A.H., et al. Assessment of hepatitis C virus attitudes towards treatment among methadone maintenance treatment program staff 2010.
52. Treloar C., Holt M. Drug treatment client's readiness for hepatitis C treatment: Implications for expanding treatment services in drug and alcohol settings. Australian Health Review 2008, 32:570-576.
53. Walley A.Y., White M.C., Kushel M.B., et al. Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment 2005, 28:181-187.
54. Wong J.B., McQuillan G.M., McHutchison J.G., Poynard T. Estimating future hepatitis C morbidity, mortality and cost in the United States. American Journal of Public Health 2000, 90:1562-1569.